BeOne Medicines Capital Expenditures (CapEx) Growth & History (ONC)
BeOne Medicines's capital expenditures (capex) was $185.8M for fiscal 2025.
View full BeOne Medicines company overviewBeOne Medicines annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $185.8M | −$306.8M | −62.28% |
| 2024 | 2024-12-31 | $492.7M | −$69.2M | −12.32% |
| 2023 | 2023-12-31 | $561.9M | $236.5M | +72.66% |
| 2022 | 2022-12-31 | $325.4M | $62.5M | +23.77% |
| 2021 | 2021-12-31 | $262.9M | $145.4M | +123.77% |
| 2020 | 2020-12-31 | $117.5M | $27.9M | +31.13% |
| 2019 | 2019-12-31 | $89.6M | $19.3M | +27.50% |
| 2018 | 2018-12-31 | $70.3M | $23.9M | +51.56% |
| 2017 | 2017-12-31 | $46.4M | $22.9M | +97.32% |
| 2016 | 2016-12-31 | $23.5M | $18.2M | +342.27% |
| 2015 | 2015-12-31 | $5.3M | $4.7M | +712.54% |
| 2014 | 2014-12-31 | $654,000 | — | — |
BeOne Medicines quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $27.5M | −$16.4M | −37.31% |
| Q1 2026 | 2026-03-31 | $40.8M | −$15.6M | −27.69% |
| Q4 2025 | 2025-12-31 | $37.5M | −$55.0M | −59.43% |
| Q3 2025 | 2025-09-30 | $48.1M | −$85.6M | −64.02% |
| Q2 2025 | 2025-06-30 | $43.8M | −$66.1M | −60.14% |
| Q1 2025 | 2025-03-31 | $56.4M | −$100.2M | −63.98% |
| Q4 2024 | 2024-12-31 | $92.5M | −$64.5M | −41.08% |
| Q3 2024 | 2024-09-30 | $133.7M | −$24.2M | −15.35% |
| Q2 2024 | 2024-06-30 | $110.0M | −$11.5M | −9.48% |
| Q1 2024 | 2024-03-31 | $156.6M | $31.0M | +24.68% |
| Q4 2023 | 2023-12-31 | $157.0M | $35.6M | +29.34% |
| Q3 2023 | 2023-09-30 | $157.9M | $49.2M | +45.31% |
| Q2 2023 | 2023-06-30 | $121.5M | $71.2M | +141.54% |
| Q1 2023 | 2023-03-31 | $125.6M | $80.5M | +178.27% |
| Q4 2022 | 2022-12-31 | $121.4M | $6.4M | +5.55% |
| Q3 2022 | 2022-09-30 | $108.7M | $41.6M | +62.07% |
| Q2 2022 | 2022-06-30 | $50.3M | $11.8M | +30.52% |
| Q1 2022 | 2022-03-31 | $45.1M | $2.7M | +6.47% |
| Q4 2021 | 2021-12-31 | $115.0M | $80.3M | +231.46% |
| Q3 2021 | 2021-09-30 | $67.0M | $38.4M | +133.75% |
| Q2 2021 | 2021-06-30 | $38.5M | $5.9M | +18.18% |
| Q1 2021 | 2021-03-31 | $42.4M | $20.9M | +96.86% |
| Q4 2020 | 2020-12-31 | $34.7M | $19.2M | +124.32% |
| Q3 2020 | 2020-09-30 | $28.7M | −$2.2M | −7.10% |
| Q2 2020 | 2020-06-30 | $32.6M | $11.2M | +52.03% |
| Q1 2020 | 2020-03-31 | $21.5M | −$295,000 | −1.35% |
| Q4 2019 | 2019-12-31 | $15.5M | −$7.8M | −33.50% |
| Q3 2019 | 2019-09-30 | $30.9M | $4.2M | +15.54% |
| Q2 2019 | 2019-06-30 | $21.4M | $10.8M | +102.08% |
| Q1 2019 | 2019-03-31 | $21.8M | $12.1M | +125.12% |
| Q4 2018 | 2018-12-31 | $23.3M | $4.3M | +22.82% |
| Q3 2018 | 2018-09-30 | $26.7M | $8.2M | +43.97% |
| Q2 2018 | 2018-06-30 | $10.6M | $6.8M | +178.34% |
| Q1 2018 | 2018-03-31 | $9.7M | $4.6M | +91.32% |
| Q4 2017 | 2017-12-31 | $18.9M | $10.9M | +134.84% |
| Q3 2017 | 2017-09-30 | $18.6M | $11.9M | +177.76% |
| Q2 2017 | 2017-06-30 | $3.8M | −$1.6M | −30.10% |
| Q1 2017 | 2017-03-31 | $5.1M | $1.8M | +53.44% |
| Q4 2016 | 2016-12-31 | $8.1M | $4.6M | +135.59% |
| Q3 2016 | 2016-09-30 | $6.7M | $5.8M | +673.38% |
| Q2 2016 | 2016-06-30 | $5.5M | $3.3M | +147.50% |
| Q1 2016 | 2016-03-31 | $3.3M | $71,000 | +2.20% |
| Q4 2015 | 2015-12-31 | $3.4M | — | — |
| Q3 2015 | 2015-09-30 | $864,000 | — | — |
| Q2 2015 | 2015-06-30 | $2.2M | — | — |
| Q1 2015 | 2015-03-31 | $3.2M | — | — |
BeOne Medicines capital expenditures (capex) trends
Over the last five fiscal years, BeOne Medicines's capital expenditures (capex) increased from $117.5M to $185.8M, a change of $68.3M. The latest reported quarter, Q2 2026, shows $27.5M.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BeOne Medicines source filings ↗